Major hurdles in comparing HER-2 IHC studies in CRC are the variety of antibodies used as well as how technical issues are differently handled across protocols such as tissue fixation, slide storage procedures, antigen retrieval, and incubation time. The gene discussed is ERBB2; the disease is colorectal carcinoma.